IBIO-100 / Medical University of South Carolina, iBio - LARVOL DELTA

iBio (IBIO) Q2 2021 Earnings Call Transcript (The Motley Fool) - “Patent claims are foundational to our work on antifibrotic therapies to support the development of our product candidate IBIO-100 for the treatment of...idiopathic pulmonary fibrosis as potential lead indications. We continue to make preparations to launch the last of our IND-enabling studies which will be followed by GMP manufacturing….We have sort of a traditional mouse model which we use for testing against idiopathic pulmonary fibrosis, where we saw really good results versus the standards of care right now, nintedanib and pirfenidone….On diseased human lung explants, our data was really good.”

Preclinical • Idiopathic Pulmonary Fibrosis

Therapeutics IBIO-100 - "Systemic sclerosis is a rare chronic disease of uncertain etiology characterized by diffuse fibrosis and vascular abnormalities in the skin, joints, and internal organs....The lead candidates are a fusion of the endostatin derived E4 antifibrotic peptide to the hinge and heavy chain of human IgG1. Based upon work by Dr. Carol Feghali-Bostwick, IBIO-100 candidates have been shown to be effective using infusion and oral administration schemes in animal models, a novel aspect of a biotherapeutic protein of its type."

Systemic Sclerosis

US Patent Issued for iBio’s Method of Boosting Anti-fibrotic Endostatin-derived Peptides (Pulmonary Fibrosis News) - "These peptides, which have been shown to possess strong anti-fibrotic or anti-scarring properties, make up part of IBIO-100, an experimental therapy that iBio is currently developing for the treatment of fibrotic disorders, including idiopathic pulmonary fibrosis and systemic scleroderma....When given orally to animal models, endostatin-derived peptides were able to halt and even reverse tissue scarring, according to a study published in 2012, by Carol Feghali-Bostwick, PhD...Following these observations, iBio acquired the licenses and intellectual rights over these patented compounds from Feghali-Bostwick and started developing its own endostatin-derived peptides."

Patent • Systemic Sclerosis

iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis (GlobeNewswire) - "iBio, Inc....today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,844,392, entitled 'Materials and Methods for Producing Endostatin Fusion Polypeptides in Plant Cells,' which, amongst other claims, covers a novel expression cassette that enhances the yield of endostatin fragments and variants using iBio’s FastPharming® System....The Company is developing such a molecule as 'IBIO-100' for the treatment of fibrotic disorders, including systemic scleroderma and idiopathic pulmonary fibrosis. The ‘392 Patent contains 19 claims and expires in June 2036....iBio plans to conduct IND-enabling studies on IBIO-100 in 2021."

Patent • Preclinical • Idiopathic Pulmonary Fibrosis • Systemic Sclerosis

IBIO-100 Systemic Scleroderma and Other Fibrotic Diseases - "Based upon the work...by iBio's collaborator Dr. Carol Feghali-Bostwick, IBIO-100 has been shown to be effective using infusion and oral administration schemes in animal models, a novel aspect of a biotherapeutic protein of its type."

Systemic Sclerosis

iBio, Inc. holds Annual Meeting in College Station, Texas (MarketWired) - "Mr. Erwin also described the rationale for the Company's selection of systemic sclerosis as its first clinical indication in the fibrotic disease area...He disclosed and summarized the Company's pre-IND meeting with the FDA in December, 2015...iBio's collaborator, and the lead inventor of IBIO-CFB03, Dr. Carol Feghali-Bostwick...described the results of her use of human tissue explants in her research and discovery efforts and the significance of those results in providing confidence in the clinical prospects for IBIO-CFB03."

Conference • Pipeline update • Systemic Sclerosis

Three recent iBioLaunch platform achievements to be presented at PBVAB 2015 Conference in Lausanne, Switzerland (Marketwire) - "On June 8, iBio's Chief Scientific Officer, Dr. Terence Ryan, will explain the rationale for iBio's selection of iBIO-CFB03 as its lead clinical candidate for its first fibrotic disease indication. He will describe the use of iBioLaunch technology to create recombinant versions of its peptide product...Dr. Ryan also will provide an update on iBio's clinical strategy and timeline for iBio's fibrotic disease product portfolio."

Conference • Systemic Sclerosis